Study of hepatomiR Test to Predict Liver Complications in Adults with Advanced Chronic Liver Disease

What this Trial Is About

Researchers are gathering data on hepatomiR, a CE-certified diagnostic test designed to assess liver-related outcomes. The study focuses on patients with compensated advanced chronic liver disease cACLD of any cause. Its purpose is to establish a cut-off value for hepatomiR that predicts specific liver decompensation events such as ascites, variceal hemorrhage, and hepatic encephalopathy. This aims to improve understanding of factors causing decompensation and support future risk management and treatment approaches. The study involves patients who undergo the hepatomiR test, which measures levels of specific microRNAs in plasma samples to calculate a liver function score. Participants are outpatients at the Clinical Department of Internal Medicine II, University Hospital St. Plten. The study will observe outcomes over a 12-month period without administering additional treatments. During the study, researchers will monitor the occurrence of hepatic decompensation events, hospital and intensive care admissions, development of liver cancers, and deaths. Data collection includes clinical assessments and monitoring liver disease progression. The total participation covers at least 12 months of follow-up to evaluate these outcomes and understand the predictive value of hepatomiR.

hepatomiR cACLD Study